Diabetes
| Chronic kidney disease
Diabetes
Chronic kidney disease
FLOW: Kidney outcome results for GLP-1RA
book_2
Source:
ADA 2024 - Symposium
calendar_today
Published on Medfyle:
July 2024
import_contacts
4
min
In this medfyle
The first dedicated kidney outcomes trial with a GLP-1RA has shown clear positive efficacy in patients with T2D and CKD. New data shared at ADA 2024 showcase the efficacy across both kidney and CV outcomes, with clear benefit across patient subgroups.
About this Medfyle
Read more
arrow_downward
Hide
arrow_upward
©2024 Medfyle. All rights reserved.
Source: The First Dedicated Kidney Outcome Trial with a GLP-1 Receptor Agonist—Once-Weekly Semaglutide and the FLOW Trial Results Symposium. ADA 2024.
The information and data provided is for information purposes only. The author(s) of the original original presentation had no involvement in the creation of this content.
